Janus Henderson Group PLC Acquires 2,610,118 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Janus Henderson Group PLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 72.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,198,689 shares of the medical equipment provider’s stock after purchasing an additional 2,610,118 shares during the quarter. Janus Henderson Group PLC owned 8.92% of Lantheus worth $554,583,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Farallon Capital Management LLC boosted its stake in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after buying an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Reinhart Partners LLC. grew its stake in Lantheus by 9.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after purchasing an additional 123,282 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider’s stock worth $120,510,000 after purchasing an additional 30,891 shares during the last quarter. Finally, Swedbank AB raised its stake in shares of Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 1.8 %

Shares of LNTH stock opened at $81.86 on Friday. Lantheus Holdings, Inc. has a 12-month low of $75.00 and a 12-month high of $126.89. The company has a market capitalization of $5.61 billion, a PE ratio of 13.62 and a beta of 0.23. The firm has a 50 day moving average price of $99.57 and a two-hundred day moving average price of $94.25.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. The business’s revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the business posted $1.69 earnings per share. As a group, research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Activity

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,109 shares of company stock valued at $6,016,046. 2.00% of the stock is owned by company insiders.

Analyst Ratings Changes

LNTH has been the topic of a number of recent analyst reports. B. Riley lowered their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, March 21st. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday. JMP Securities reiterated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial lowered their price target on Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research report on Thursday. Seven analysts have rated the stock with a buy rating, According to MarketBeat, Lantheus has a consensus rating of “Buy” and a consensus price target of $132.67.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.